Alogliptin + metformin combination for the treatment of type 2 diabetes mellitus

References

• American Diabetes Association. Fast facts: data and statistics about diabetes [Internet]; [cited 2015 May 4]. Available from: professional.diabetes.org/facts.
   Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2015. Diabetes Care. 2015;38(Suppl 1):S1–93.
   PubMed Web of Science ®Google Scholar
• Elrick H, Stimmler L, Hlad CJ, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–1082.
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W. The incretin concept today. Diabetologia. 1979;16(2):75–85.
   PubMed Web of Science ®Google Scholar
• Dupre J, Ross SA, Watson D, et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973;37(5):826–828.
   PubMed Web of Science ®Google Scholar
• Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 1983;302(5910):716–718.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492–498.
   PubMed Web of Science ®Google Scholar
• Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705.
   PubMed Web of Science ®Google Scholar
• Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes. 1993;42(5):658–661.
   PubMed Web of Science ®Google Scholar
• Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab. 2009;23(4):487–498.
   PubMed Web of Science ®Google Scholar
• Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 2004;53(9):2181–2189.
   PubMed Web of Science ®Google Scholar
• Wikimedia Images; [cited 2015 Jun 1]. Available from: www.wikimedia.org.
   Google Scholar
• Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30(3):499–512.
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71(11):1441–1467.
   PubMed Web of Science ®Google Scholar
• Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51(8):501–514.
   PubMed Web of Science ®Google Scholar
• Seino Y, Fujita T, Hiroi S, et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011;27(9):1781–1792.
   PubMed Web of Science ®Google Scholar
• Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. 2013;36(7):2126–2132.
   PubMed Web of Science ®Google Scholar
• Setter SM, Iltz JL, Thams J, et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther. 2003;25(12):2991–3026.
   PubMed Web of Science ®Google Scholar
• Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30(3):513–527.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010;49(9):573–588.
   PubMed Web of Science ®Google Scholar
• Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther. 2010;48(1):46–58.
   PubMed Web of Science ®Google Scholar
• Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment [abstract 538-P]. 68th Annual Scientific Sessions of the American Diabetes Association. Diabetes. 2008;57:538.
   Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30:359–371.
   PubMed Web of Science ®Google Scholar
• Takeda Pharmacueticals America, Inc. Kazano^TM (alogliptin and metformin HCl) [package insert]. Deerfield (IL): Takeda Pharmaceuticals America, Inc.; 2013.
   Google Scholar
• Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46–55.
   PubMed Web of Science ®Google Scholar
• Seino Y, Miyata Y, Hiroi S, et al. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab. 2012;14(10):927–936.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014;16:613–621.
   PubMed Web of Science ®Google Scholar
• Del Prato S, Camisasca R, Wilson C, et al. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16:1239–1246.
   PubMed Web of Science ®Google Scholar
• Giorda CB, Sacerdote C, Nada E, et al. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2015;48:461–471.
   PubMed Web of Science ®Google Scholar
• Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;348:g2366.
   PubMed Web of Science ®Google Scholar
• White WB, Bakris GL, Bergenstal RM, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162(4):620–626.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. Jama. 2005;294:2581–2586.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471.
   PubMed Web of Science ®Google Scholar
• Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J. 1999;138(5 Pt 1):S346–52.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. [cited May 5, 2015]. Available from: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
   Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689–697.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel A, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicenter, randomized, double-blind trial. Lancet. 2015;385(9982):2067–2076.
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Varughese GI, Scarpello JH, et al. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? Bmj. 2007;335(7618):508–512.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;14(4):CD002967.
   Google Scholar
• Roberts F, Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother. 2007;41:642–646.
   PubMed Web of Science ®Google Scholar
• Pongwecharak J, Tengmeesri N, Malanusorn N, et al. Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. Pharm World Sci. 2009;31(4):481–486.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease. Jama. 2014;312:2668–2675.
   PubMed Web of Science ®Google Scholar
• Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16:30–37.
   PubMed Web of Science ®Google Scholar
• Garcia-Perez LE, Maria A, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175–194.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A comparative effectiveness study of major glycemia-lowering medications for treatment of type 2 diabetes (GRADE) [Internet]. [cited May 29 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01794143.
   Google Scholar